Rifampin is a rifamycin-class antibacterial used primarily in tuberculosis treatment and meningococcal carrier eradication. It is a semisynthetic rifamycin derivative whose antimicrobial activity includes inhibition of mycobacterial DNA-dependent RNA polymerase. U.S. brand Rifadin capsules were initially approved in 1971.
A vaccine and two novel tuberculosis treatments are advancing through Phase III trials, marking renewed momentum in TB research. Tuberculosis claims over 1.25 million lives annually with 10.6 million new cases in 2023, while current treatments face challenges of high pill burden, toxicity, and rising resistance.
The World Health Organization has recommended new portable TB diagnostic tests that deliver results in under an hour, while researchers developed an inhalable nanoparticle treatment that could replace daily pills. TB remains the world's deadliest infectious disease, killing 1.2 million people in 2024 despite being preventable and curable.
Researchers have developed an inhalable nanoparticle system for delivering rifampin directly to the lungs, potentially reducing tuberculosis treatment from daily to once-weekly dosing while lowering side effects and improving drug effectiveness.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07600775 |
A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07595042 |
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07550621 |
Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07357610 |
An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants |
RECRUITING | PHASE1 |
| NCT07253688 |
Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus |
RECRUITING | PHASE3 |
| NCT07242781 |
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants |
RECRUITING | PHASE1 |
| NCT07018635 |
A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants |
COMPLETED | PHASE1 |
| NCT06917495 |
Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis |
NOT_YET_RECRUITING | PHASE2 |
| NCT06835465 |
A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants |
COMPLETED | PHASE1 |
| NCT06701136 |
Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults |
NOT_YET_RECRUITING | PHASE1 |
